<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2150">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119114</url>
  </required_header>
  <id_info>
    <org_study_id>MRI in dementia</org_study_id>
    <nct_id>NCT05119114</nct_id>
  </id_info>
  <brief_title>Volumetric Magnetic Resonance Imaging in Dementia</brief_title>
  <official_title>Role of Volumetric Magnetic Resonance Imaging in Evaluation of Different Types of Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dementia is a term for the impaired ability to remember, think, or make decisions that&#xD;
      interferes with doing everyday activities. Alzheimer's disease is the most common type of&#xD;
      dementia. Though dementia mostly affects older adults, it is not a part of normal aging. This&#xD;
      study aims to assess the role of volumetric MRI in evaluation of different types of dementia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurocognitive disorders (dementia) are prevalent clinical problems. With the increase in&#xD;
      average life expectancy, its prevalence is rising at an alarming rate. In 2005, an estimated&#xD;
      24 million people around the world suffered from dementia, and that number is expected to&#xD;
      double every 20 years. By 2040, it is predicted that over 81 million people worldwide will&#xD;
      suffer from dementia. Most experts agree that treatment will be most beneficial if applied&#xD;
      early, before significant, potentially irreversible neurodegeneration and functional&#xD;
      impairment has occurred.&#xD;
&#xD;
      Clinical symptoms of most subtypes of dementia arise from progressive neuron and synapse&#xD;
      loss, with the resulting tissue atrophy. Brain magnetic resonance imaging (MRI) is regularly&#xD;
      used in diagnosing dementia as it visualises the structural changes caused by&#xD;
      neurodegeneration. It is key in defining subtle differences between healthy and pathological&#xD;
      cerebral volume loss and between dementia subtypes.&#xD;
&#xD;
      Visual assessment of brain atrophy patterns is commonly supported through the use of visual&#xD;
      rating scales. However, these scales have a subjective element and their application relies&#xD;
      heavily on the prior experience of the radiologist using them. And they have poor sensitivity&#xD;
      to subtle or prodromal changes and have ceiling and/or floor effects.&#xD;
&#xD;
      Application of quantitative volumetric reporting tools, which automatically quantify an&#xD;
      individual patient's regional brain volumes and compare them to healthy populations, can&#xD;
      potentially help in interpretation of the severity and distribution of brain atrophy and&#xD;
      contextualize their findings by referencing normative brain volumes in healthy populations.&#xD;
      This will improve the accuracy of radiological diagnosis of different subtypes of dementia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MRI Accuracy in dementia</measure>
    <time_frame>1 week</time_frame>
    <description>Assess the accuracy of magnetic resonance imaging in differentiate between normal aging and cases of dementia</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dementia</condition>
  <condition>Alzheimer Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>A standardized multi-parametric MRI protocol will be implemented for all patients. All sequences will be acquired on a 1.5 Tesla scanner. After completion of the MRI study, the digital imaging and communication data will be sent to a diagnostic workstation for post-processing and analysis. Patients of the study will be subjected to detailed structural MRI for detection of signs of neurodegenerative changes. Volumetric high-resolution 3D scans will be used for quantitative study.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be conducted over the period of 2 years during which all available cases&#xD;
        with dementia presented to the Neurology Centre at Assiut university well be investigated.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with any type of dementia.&#xD;
&#xD;
          -  Patients with mini mental state examination equal or more than 18.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with contra-indications to MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hosam A Youssif, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Abdel-Razzak, McS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Abdel-Razzak, McS</last_name>
    <phone>01147160733</phone>
    <phone_ext>+20</phone_ext>
    <email>Ahmedabdelrazzak90@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Abdeltawab, MD</last_name>
    <phone>+201009319309</phone>
    <email>dr.m.tawab@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005 Dec 17;366(9503):2112-7.</citation>
    <PMID>16360788</PMID>
  </results_reference>
  <results_reference>
    <citation>Fennema-Notestine C, Hagler DJ Jr, McEvoy LK, Fleisher AS, Wu EH, Karow DS, Dale AM; Alzheimer's Disease Neuroimaging Initiative. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp. 2009 Oct;30(10):3238-53. doi: 10.1002/hbm.20744.</citation>
    <PMID>19277975</PMID>
  </results_reference>
  <results_reference>
    <citation>Duchesne S, Caroli A, Geroldi C, Barillot C, Frisoni GB, Collins DL. MRI-based automated computer classification of probable AD versus normal controls. IEEE Trans Med Imaging. 2008 Apr;27(4):509-20. doi: 10.1109/TMI.2007.908685.</citation>
    <PMID>18390347</PMID>
  </results_reference>
  <results_reference>
    <citation>Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO, Frisoni GB, Scheltens P; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017 Apr;52:167-182.e1. doi: 10.1016/j.neurobiolaging.2016.05.024. Review.</citation>
    <PMID>28317647</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed Abdel-Tawab Mohamed</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

